The latest price target for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) was reported by Maxim Group on July 23, 2025. The analyst firm set a price target for $0.00 expecting BCLI to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) was provided by Maxim Group, and BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. downgraded their hold rating.

The last upgrade for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. happened on July 11, 2024 when Maxim Group raised their price target to $2. Maxim Group previously had a hold for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc..

The last downgrade for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. happened on July 23, 2025 when Maxim Group changed their price target from N/A to N/A for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc..

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc., and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. was filed on July 23, 2025 so you should expect the next rating to be made available sometime around July 23, 2026.

While ratings are subjective and will change, the latest BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) rating was a downgraded with a price target of $0.00 to $0.00. The current price BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) is trading at is $0.69, which is out of the analyst’s predicted range.